53(top 10%)
PR articles
1.6K(top 5%)
PR citations
22(top 5%)
PR h-index
23(top 5%)
h-index
60
documents
2.1K
doc citations
604
citing journals

Top Articles

#TitleJournalYearPR Citations
1Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine2022278
2Variant Cystic Fibrosis Phenotypes in the Absence ofCFTRMutationsNew England Journal of Medicine2002110
3Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcherJournal of Cystic Fibrosis201799
4Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of LifeJAMA Pediatrics201787
5Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GIJournal of Cystic Fibrosis202379
6Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United StatesChest201776
7Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary ExacerbationsJournal of Cystic Fibrosis201775
8Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohortJournal of Cystic Fibrosis201271
9Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbationsJournal of Cystic Fibrosis201767
10Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center NetworkBMJ Quality and Safety201461
11Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosisThorax201656
12Clinical outcomes after initial pseudomonas acquisition in cystic fibrosisPediatric Pulmonology201555
13Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic InflammationAnnals of the American Thoracic Society201553
14Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patientsJournal of Cystic Fibrosis202152
15Baseline Characteristics and Factors Associated With Nutritional and Pulmonary Status at Enrollment in the Cystic Fibrosis EPIC Observational CohortPediatric Pulmonology201050
16Use of Phage Display To Identify Potential Pseudomonas aeruginosa Gene Products Relevant to Early Cystic Fibrosis Airway InfectionsInfection and Immunity200549
17Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical TrialAmerican Journal of Respiratory and Critical Care Medicine201838
18Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosisJournal of Cystic Fibrosis202335
19Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical TrialAnnals of the American Thoracic Society202134
20Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect studyJournal of Cystic Fibrosis202029
21Advancing clinical development pathways for new CFTR modulators in cystic fibrosisThorax201628
22Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosisJournal of Cystic Fibrosis201023
23Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short‐term tolerability, adherence, and safetyPediatric Pulmonology201122
24Cystic Fibrosis: The Dawn of a New Therapeutic EraAmerican Journal of Respiratory and Critical Care Medicine201720
25Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug developmentJournal of Cystic Fibrosis202120
26Recurrent and Destructive Nasal Polyposis in 2 Siblings: A Possible Case of Woakes' SyndromeOtolaryngology - Head and Neck Surgery200419
27Utilization of electronic patient-reported outcome measures in cystic fibrosis research: Application to the GALAXY studyJournal of Cystic Fibrosis202116
28Outcomes and Treatment of Chronic Methicillin-ResistantStaphylococcus aureusDiffers by Staphylococcal Cassette Chromosomemec(SCCmec) Type in Children With Cystic FibrosisJournal of the Pediatric Infectious Diseases Society201515
29Update in Cystic Fibrosis 2018American Journal of Respiratory and Critical Care Medicine201913
30Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551DJournal of Cystic Fibrosis202213
31Testing the effects of combining azithromycin with inhaled tobramycin forP. aeruginosain cystic fibrosis: a randomised, controlled clinical trialThorax202212
32Common clinical features of CF (respiratory disease and exocrine pancreatic insufficiency)Presse Medicale201711
33Pulmonary findings in infants with cystic fibrosis during the first year of life: Results from the Baby Observational and Nutrition Study (BONUS) cohort studyPediatric Pulmonology201911
34Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosisJournal of Cystic Fibrosis201911
35Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severityJournal of Cystic Fibrosis202011
36Infants with cystic fibrosis have altered fecal functional capacities with potential clinical and metabolic consequencesBMC Microbiology202111
37Built environment factors predictive of early rapid lung function decline in cystic fibrosisPediatric Pulmonology202311
38Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftorJournal of Cystic Fibrosis202410
39The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development networkJournal of Cystic Fibrosis20217
40Upper airway microbiota development in infants with cystic fibrosis diagnosed by newborn screenJournal of Cystic Fibrosis20235
41Rates of adverse and serious adverse events in children with cystic fibrosisJournal of Cystic Fibrosis20214
42Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT studyJournal of Cystic Fibrosis20244
43Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosisJournal of Cystic Fibrosis20243
44Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational StudyAnnals of the American Thoracic Society03
45Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammationCell Host and Microbe20253
46Role of hyperglycemia in cystic fibrosis pulmonary exacerbationsJournal of Cystic Fibrosis20232
47Clinical outcomes at 9–10 years of age in children born with cystic fibrosis transmembrane conductance regulator related metabolic syndromePediatric Pulmonology20242
48Assessment of patients' baseline cystic fibrosis knowledge levels following translation and adaptation of the CF R.I.S.E translation program into TurkishPediatric Pulmonology20242
49Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed TherapiesAnnals of the American Thoracic Society20161
50Trial design of bacteriophage therapy for nontuberculous mycobacteria pulmonary disease in cystic fibrosis: The POSTSTAMP studyJournal of Cystic Fibrosis20251